Therefore, blockade of this pathway by specific MEK-inhibitors leads to nuclear vRNP retention (Pleschka et al., 2001; Droebner et al., 2011) and different MEK-inhibitors, which are already approved for cancer treatment (Trametinib®) or used earlier in clinical trials (CI-1040), have shown a high anti-IV activity (Haasbach et al., 2017; Schrader et al., 2018). Here, MAP2K7 is linked to cancer.